- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 25/16 - Anti-Parkinson drugs
Patent holdings for IPC class A61P 25/16
Total number of patents in this class: 5589
10-year publication summary
|
170
|
309
|
383
|
330
|
372
|
392
|
377
|
370
|
344
|
123
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| F. Hoffmann-La Roche AG | 7828 |
75 |
| Takeda Pharmaceutical Company Limited | 2719 |
57 |
| Hoffmann-La Roche Inc. | 3679 |
51 |
| H. Lundbeck A/S | 1242 |
47 |
| Janssen Pharmaceutica N.V. | 3235 |
38 |
| The Regents of the University of California | 20506 |
37 |
| Sumitomo Pharma Co., Ltd. | 549 |
36 |
| Genentech, Inc. | 4061 |
29 |
| Taisho Pharmaceutical Co., Ltd. | 859 |
29 |
| Sumitomo Dainippon Pharma Co., Ltd. | 211 |
27 |
| Pfizer Inc. | 3362 |
26 |
| Bristol-myers Squibb Company | 4809 |
25 |
| Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 857 |
25 |
| Merck Sharp & Dohme LLC | 3708 |
25 |
| Novartis AG | 10350 |
24 |
| The Johns Hopkins University | 5813 |
22 |
| BIAL - Portela & CA, S.A. | 214 |
22 |
| Osaka University | 3309 |
22 |
| Centre National de La Recherche Scientifique | 10870 |
20 |
| Daiichi Sankyo Company, Limited | 1885 |
20 |
| Other owners | 4932 |